{"id":2815,"date":"2025-11-29T06:11:31","date_gmt":"2025-11-29T06:11:31","guid":{"rendered":"https:\/\/dr7.ai\/blog\/?p=2815"},"modified":"2025-11-29T06:11:33","modified_gmt":"2025-11-29T06:11:33","slug":"ai-in-drug-discovery-2025-real-world-impact-regulatory-truth","status":"publish","type":"post","link":"https:\/\/dr7.ai\/blog\/model\/ai-in-drug-discovery-2025-real-world-impact-regulatory-truth\/","title":{"rendered":"AI in Drug Discovery 2025: Real-World Impact &amp; Regulatory Truth"},"content":{"rendered":"\n<p><strong>Disclaimer:<\/strong><\/p>\n\n\n\n<p>The content on this website is for informational and educational purposes only and is intended to help readers understand AI technologies used in healthcare settings. It does not provide medical advice, diagnosis, treatment, or clinical guidance. Any medical decisions must be made by qualified healthcare professionals. AI models, tools, or workflows described here are assistive technologies, not substitutes for professional medical judgment. Deployment of any AI system in real clinical environments requires institutional approval, regulatory and legal review, data privacy compliance (e.g., HIPAA\/GDPR), and oversight by licensed medical personnel. DR7.ai and its authors assume no responsibility for actions taken based on this content.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\" \/>\n\n\n\n<p>When I first started collaborating with translational teams on <strong>AI in drug discovery<\/strong>, I was struck by the same pattern over and over: breathtaking demo models, followed by regulatory gridlock and disappointing wet-lab validation. The gap wasn&#8217;t imagination, it was evidence, reproducibility, and integration into existing GxP workflows.<\/p>\n\n\n\n<p>In this text, I&#8217;ll walk through how I actually see AI reshaping drug discovery in regulated settings: what&#8217;s working, what keeps failing validation, how we&#8217;re navigating FDA expectations, and where I&#8217;d invest engineering time if I were rebuilding a drug-discovery stack today.<\/p>\n\n\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 ez-toc-wrap-left counter-hierarchy ez-toc-counter ez-toc-transparent ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69e1c2c630a57\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"ez-toc-cssicon\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69e1c2c630a57\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/dr7.ai\/blog\/model\/ai-in-drug-discovery-2025-real-world-impact-regulatory-truth\/#Overcoming_Challenges_in_Drug_Discovery_with_AI\" >Overcoming Challenges in Drug Discovery with AI<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/dr7.ai\/blog\/model\/ai-in-drug-discovery-2025-real-world-impact-regulatory-truth\/#Addressing_the_Large_Search_Space_and_High_Failure_Rates_in_Pharmaceutical_R_D\" >Addressing the Large Search Space and High Failure Rates in Pharmaceutical R&amp;D<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/dr7.ai\/blog\/model\/ai-in-drug-discovery-2025-real-world-impact-regulatory-truth\/#Tackling_Time_and_Cost_Barriers_in_Drug_Development_through_AI_Innovation\" >Tackling Time and Cost Barriers in Drug Development through AI Innovation<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/dr7.ai\/blog\/model\/ai-in-drug-discovery-2025-real-world-impact-regulatory-truth\/#Leveraging_AI_in_Early-Stage_Drug_Discovery_Research\" >Leveraging AI in Early-Stage Drug Discovery Research<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/dr7.ai\/blog\/model\/ai-in-drug-discovery-2025-real-world-impact-regulatory-truth\/#How_AI_Enhances_Target_Identification_in_Drug_Discovery\" >How AI Enhances Target Identification in Drug Discovery<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/dr7.ai\/blog\/model\/ai-in-drug-discovery-2025-real-world-impact-regulatory-truth\/#The_Role_of_Generative_AI_Models_in_Molecule_Design_and_Optimization\" >The Role of Generative AI Models in Molecule Design and Optimization<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/dr7.ai\/blog\/model\/ai-in-drug-discovery-2025-real-world-impact-regulatory-truth\/#AI_Applications_in_Preclinical_and_Clinical_Drug_Development\" >AI Applications in Preclinical and Clinical Drug Development<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/dr7.ai\/blog\/model\/ai-in-drug-discovery-2025-real-world-impact-regulatory-truth\/#Utilizing_AI_to_Predict_Drug-Target_Interactions_and_Toxicity_Risks\" >Utilizing AI to Predict Drug-Target Interactions and Toxicity Risks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/dr7.ai\/blog\/model\/ai-in-drug-discovery-2025-real-world-impact-regulatory-truth\/#Enhancing_Clinical_Trial_Analysis_with_AI-Driven_Insights\" >Enhancing Clinical Trial Analysis with AI-Driven Insights<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/dr7.ai\/blog\/model\/ai-in-drug-discovery-2025-real-world-impact-regulatory-truth\/#Success_Stories_AI-Driven_Breakthroughs_in_Drug_Discovery\" >Success Stories: AI-Driven Breakthroughs in Drug Discovery<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/dr7.ai\/blog\/model\/ai-in-drug-discovery-2025-real-world-impact-regulatory-truth\/#Promising_Drug_Candidates_Discovered_through_AI_Technology\" >Promising Drug Candidates Discovered through AI Technology<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/dr7.ai\/blog\/model\/ai-in-drug-discovery-2025-real-world-impact-regulatory-truth\/#Leading_AI_Tools_Revolutionizing_Pharmaceutical_R_D_eg_AlphaFold\" >Leading AI Tools Revolutionizing Pharmaceutical R&amp;D (e.g., AlphaFold)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/dr7.ai\/blog\/model\/ai-in-drug-discovery-2025-real-world-impact-regulatory-truth\/#The_Future_of_AI_in_Drug_Discovery_Benefits_and_Ongoing_Challenges\" >The Future of AI in Drug Discovery: Benefits and Ongoing Challenges<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/dr7.ai\/blog\/model\/ai-in-drug-discovery-2025-real-world-impact-regulatory-truth\/#Accelerating_Drug_Development_and_Personalizing_Treatments_with_AI\" >Accelerating Drug Development and Personalizing Treatments with AI<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/dr7.ai\/blog\/model\/ai-in-drug-discovery-2025-real-world-impact-regulatory-truth\/#Overcoming_Validation_and_Regulatory_Challenges_in_AI-Driven_Drug_Discovery\" >Overcoming Validation and Regulatory Challenges in AI-Driven Drug Discovery<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/dr7.ai\/blog\/model\/ai-in-drug-discovery-2025-real-world-impact-regulatory-truth\/#Frequently_Asked_Questions_about_AI_in_Drug_Discovery\" >Frequently Asked Questions about AI in Drug Discovery<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/dr7.ai\/blog\/model\/ai-in-drug-discovery-2025-real-world-impact-regulatory-truth\/#What_is_AI_in_drug_discovery_and_where_does_it_add_the_most_value_today\" >What is AI in drug discovery and where does it add the most value today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/dr7.ai\/blog\/model\/ai-in-drug-discovery-2025-real-world-impact-regulatory-truth\/#How_does_AI_in_drug_discovery_reduce_time_and_cost_in_pharmaceutical_R_D\" >How does AI in drug discovery reduce time and cost in pharmaceutical R&amp;D?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/dr7.ai\/blog\/model\/ai-in-drug-discovery-2025-real-world-impact-regulatory-truth\/#How_are_generative_AI_models_used_for_molecule_design_and_optimization\" >How are generative AI models used for molecule design and optimization?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/dr7.ai\/blog\/model\/ai-in-drug-discovery-2025-real-world-impact-regulatory-truth\/#What_are_the_main_regulatory_challenges_for_using_AI_in_drug_discovery\" >What are the main regulatory challenges for using AI in drug discovery?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/dr7.ai\/blog\/model\/ai-in-drug-discovery-2025-real-world-impact-regulatory-truth\/#How_can_a_pharma_or_biotech_company_practically_start_implementing_AI_in_drug_discovery\" >How can a pharma or biotech company practically start implementing AI in drug discovery?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\" id=\"overcoming-challenges-in-drug-discovery-with-ai\"><span class=\"ez-toc-section\" id=\"Overcoming_Challenges_in_Drug_Discovery_with_AI\"><\/span>Overcoming Challenges in Drug Discovery with AI<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<h3 class=\"wp-block-heading\" id=\"addressing-the-large-search-space-and-high-failure-rates-in-pharmaceutical-rampd\"><span class=\"ez-toc-section\" id=\"Addressing_the_Large_Search_Space_and_High_Failure_Rates_in_Pharmaceutical_R_D\"><\/span>Addressing the Large Search Space and High Failure Rates in Pharmaceutical R&amp;D<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n<p>In small-molecule discovery, the theoretical chemical space is often cited at 10^60\u201310^80 compounds, far beyond what traditional high\u2011throughput screening can touch. In my own work with an oncology pipeline, the team started with ~2 million purchasable compounds. Even that &#8220;small&#8221; space generated more hits than we could assay.<\/p>\n\n\n\n<p>AI helps by:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Learning structure\u2013activity relationships (SAR)<\/strong> from historical assay, ADMET, and omics data to prioritize only the few thousand compounds most likely to bind and be developable.<\/li>\n\n\n\n<li><strong>Integrating multimodal data<\/strong>, e.g., combining AlphaFold-predicted structures with transcriptomics and known pathway biology to filter out targets likely to be non\u2011druggable or redundant.<\/li>\n<\/ul>\n\n\n\n<p>Recent reviews (e.g., <strong><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10302890\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Nature 2022 on AI-based drug discovery<\/a><\/strong>, <strong><a href=\"https:\/\/www.frontiersin.org\/journals\/pharmacology\/articles\/10.3389\/fphar.2025.1597351\/full\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Front Pharmacol 2025 on machine learning applications<\/a><\/strong>) show AI models consistently enriching for actives and reducing false positives. But in my experience, the main win isn&#8217;t magic hit rates: it&#8217;s focus. You move from brute-force screening to hypothesis-driven, AI\u2011ranked campaigns that are much easier to justify to portfolio committees.<\/p>\n\n\n\n<div class=\"wp-block-uagb-image uagb-block-a44ca417 wp-block-uagb-image--layout-default wp-block-uagb-image--effect-static wp-block-uagb-image--align-none\"><figure class=\"wp-block-uagb-image__figure\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/dr7.ai\/blog\/wp-content\/uploads\/2025\/11\/1280X1280-3-7.png\" alt=\"\" width=\"370\" height=\"368\" title=\"\" loading=\"lazy\" role=\"img\" \/><\/figure><\/div>\n\n\n<h3 class=\"wp-block-heading\" id=\"tackling-time-and-cost-barriers-in-drug-development-through-ai-innovation\"><span class=\"ez-toc-section\" id=\"Tackling_Time_and_Cost_Barriers_in_Drug_Development_through_AI_Innovation\"><\/span>Tackling Time and Cost Barriers in Drug Development through AI Innovation<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n<p>Bringing a drug to market is still a $1\u20132 billion, 10\u201315 year try. AI won&#8217;t suddenly cut that to 18 months, but it&#8217;s already shaving off expensive dead ends.<\/p>\n\n\n\n<p>On one program for an autoimmune indication, we used a multi-task model to jointly predict potency, hERG, CYP inhibition, and basic PK parameters. By filtering before synthesis, the chemistry team cut wet-lab iterations by roughly one third. That didn&#8217;t show up as a flashy headline, but it meant we <em>didn&#8217;t<\/em> push two toxic chemotypes into animal studies.<\/p>\n\n\n\n<p>Concretely, I see AI driving savings by:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Automating routine in silico triage<\/strong> (docking, similarity search, rule\u2011based filters) so expert time goes to edge cases.<\/li>\n\n\n\n<li><strong>Re\u2011using models across programs<\/strong>, a well\u2011validated ADMET or off\u2011target model can support multiple therapeutic areas with minimal retraining.<\/li>\n\n\n\n<li><strong>Reducing late\u2011stage attrition<\/strong> by better early prediction of toxicity and lack of efficacy (see <strong><a href=\"https:\/\/pubs.acs.org\/doi\/10.1021\/acsomega.5c00549\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">ACS Omega 2015 on computational toxicity prediction<\/a><\/strong> for early examples, expanded in recent surveys like <strong><a href=\"https:\/\/link.springer.com\/article\/10.1186\/s13321-024-00812-5\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">BMC Chemistry 2024 on AI in drug development<\/a><\/strong>).<\/li>\n<\/ul>\n\n\n\n<p>The caveat: the cost savings only materialize when models are integrated into decision gates, not run as side experiments that everyone politely ignores.<\/p>\n\n\n<h2 class=\"wp-block-heading\" id=\"leveraging-ai-in-earlystage-drug-discovery-research\"><span class=\"ez-toc-section\" id=\"Leveraging_AI_in_Early-Stage_Drug_Discovery_Research\"><\/span>Leveraging AI in Early-Stage Drug Discovery Research<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<h3 class=\"wp-block-heading\" id=\"how-ai-enhances-target-identification-in-drug-discovery\"><span class=\"ez-toc-section\" id=\"How_AI_Enhances_Target_Identification_in_Drug_Discovery\"><\/span>How AI Enhances Target Identification in Drug Discovery<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n<p>Target ID is where the hype can be particularly misleading. Yes, we have sophisticated graph neural networks and causal inference pipelines, but the most robust wins I&#8217;ve seen come from <strong>careful integration of multi\u2011omics with clinical phenotypes<\/strong>.<\/p>\n\n\n\n<p>For a neurodegenerative disease project, we used AI to:<\/p>\n\n\n\n<ol start=\"1\" class=\"wp-block-list\">\n<li>Ingest large GWAS datasets and public expression atlases.<\/li>\n\n\n\n<li>Build gene\u2013gene and gene\u2013phenotype networks (using methods similar to those reviewed in <strong><a href=\"https:\/\/academic.oup.com\/bib\/article\/25\/4\/bbae338\/7713723\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Brief Bioinform 2024 on AI-driven target identification<\/a><\/strong>).<\/li>\n\n\n\n<li>Rank potential targets by predicted causal impact and tractability (e.g., presence of ligandable pockets, pathway redundancy, safety clusters).<\/li>\n<\/ol>\n\n\n\n<p>The outputs didn&#8217;t &#8220;discover&#8221; a totally novel pathway: instead, they re\u2011prioritized a previously low\u2011interest kinase that now looks mechanistically central and clinically plausible. That&#8217;s typical: AI sharpens the signal, it rarely conjures something from nothing.<\/p>\n\n\n\n<p>Key practical points I emphasize with engineering teams:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Lineage tracking:<\/strong> every target ranking should be traceable back to datasets, model versions, and pre\u2011processing steps.<\/li>\n\n\n\n<li><strong>Prospective validation:<\/strong> pre\u2011register your target hypothesis and prospective wet\u2011lab validation plan: otherwise it&#8217;s cherry\u2011picking.<\/li>\n<\/ul>\n\n\n<h3 class=\"wp-block-heading\" id=\"the-role-of-generative-ai-models-in-molecule-design-and-optimization\"><span class=\"ez-toc-section\" id=\"The_Role_of_Generative_AI_Models_in_Molecule_Design_and_Optimization\"><\/span>The Role of Generative AI Models in Molecule Design and Optimization<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n<p>Generative models, VAEs, diffusion, flow\u2011based models, and large language models trained on SMILES or graphs, are now standard in early-stage discovery.<\/p>\n\n\n\n<p>I&#8217;ve worked with setups similar to <strong><a href=\"https:\/\/blogs.nvidia.com\/blog\/drug-discovery-bionemo-generative-ai\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">NVIDIA&#8217;s BioNeMo platform for drug discovery<\/a><\/strong> and academic frameworks described in recent reviews (e.g., <strong><a href=\"https:\/\/wyss.harvard.edu\/news\/from-data-to-drugs-the-role-of-artificial-intelligence-in-drug-discovery\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Wyss Institute reports on AI in drug discovery<\/a><\/strong>, <strong><a href=\"https:\/\/www.drugtargetreview.com\/article\/158593\/early-evidence-and-emerging-trends-how-ai-is-shaping-drug-discovery-and-clinical-development\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Drug Target Review 2023 on early AI evidence in drug development<\/a><\/strong>):<\/p>\n\n\n\n<figure class=\"wp-block-gallery has-nested-images columns-default is-cropped wp-block-gallery-1 is-layout-flex wp-block-gallery-is-layout-flex\">\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/dr7.ai\/blog\/wp-content\/uploads\/2025\/11\/df6db752-8da2-4de7-ad9d-ef2da0510246-1024x579.png\" alt=\"\" \/><\/figure>\n<\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>De novo ideation:<\/strong> propose scaffold\u2011diverse molecules conditioned on a target, docking score, or predicted ADMET profile.<\/li>\n\n\n\n<li><strong>Goal\u2011directed optimization:<\/strong> take a chemist&#8217;s starting scaffold and iteratively improve potency or selectivity while penalizing synthetic complexity.<\/li>\n<\/ul>\n\n\n\n<p>In one anti\u2011infective project, generative models suggested non\u2011obvious modifications around a known scaffold that maintained activity while dodging a patent thicket. Roughly 10\u201315% of AI\u2011suggested compounds survived medicinal chemistry triage and moved to synthesis, which is meaningful.<\/p>\n\n\n\n<p>But there are clear pitfalls:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Many generated molecules are <strong>chemically implausible<\/strong> or synthetically infeasible without strong constraints.<\/li>\n\n\n\n<li>Models can <strong>overfit the training chemistry<\/strong> and regurgitate near\u2011duplicates of published structures.<\/li>\n<\/ul>\n\n\n\n<p>To mitigate risk, I always insist on:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Automatic PAINS and liability filters.<\/li>\n\n\n\n<li>Retrosynthetic analysis using separate models or rule\u2011based engines.<\/li>\n\n\n\n<li>Clear documentation that generative proposals are hypotheses, not design truth.<\/li>\n<\/ul>\n\n\n<h2 class=\"wp-block-heading\" id=\"ai-applications-in-preclinical-and-clinical-drug-development\"><span class=\"ez-toc-section\" id=\"AI_Applications_in_Preclinical_and_Clinical_Drug_Development\"><\/span>AI Applications in Preclinical and Clinical Drug Development<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<h3 class=\"wp-block-heading\" id=\"utilizing-ai-to-predict-drugtarget-interactions-and-toxicity-risks\"><span class=\"ez-toc-section\" id=\"Utilizing_AI_to_Predict_Drug-Target_Interactions_and_Toxicity_Risks\"><\/span>Utilizing AI to Predict Drug-Target Interactions and Toxicity Risks<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n<p>Beyond hit finding, AI is now central to <strong>drug\u2013target interaction (DTI)<\/strong> prediction and safety profiling.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Structure-based: <\/strong>Tools leveraging<strong><a href=\"https:\/\/www.nature.com\/articles\/s41392-022-00994-0\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">AlphaFold&#8217;s breakthrough in protein structure prediction<\/a> (<a href=\"https:\/\/news.mit.edu\/2022\/alphafold-potential-protein-drug-0906\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">MIT Technology Review on AlphaFold&#8217;s drug discovery potential<\/a>, <a href=\"https:\/\/deepmind.google\/blog\/alphafold-five-years-of-impact\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">DeepMind&#8217;s five years of AlphaFold impact<\/a>) <\/strong>let us dock against predicted structures and build ML models over docking scores plus protein\u2011ligand features.<\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-gallery has-nested-images columns-default is-cropped wp-block-gallery-2 is-layout-flex wp-block-gallery-is-layout-flex\">\n<figure class=\"wp-block-image size-full\"><img fetchpriority=\"high\" decoding=\"async\" width=\"685\" height=\"702\" data-id=\"2822\" src=\"https:\/\/dr7.ai\/blog\/wp-content\/uploads\/2025\/11\/image-19.png\" alt=\"\" class=\"wp-image-2822\" srcset=\"https:\/\/dr7.ai\/blog\/wp-content\/uploads\/2025\/11\/image-19.png 685w, https:\/\/dr7.ai\/blog\/wp-content\/uploads\/2025\/11\/image-19-293x300.png 293w\" sizes=\"(max-width: 685px) 100vw, 685px\" \/><\/figure>\n<\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Ligand\u2011based:<\/strong> Deep models trained on bioactivity databases (ChEMBL, PubChem) can generalize to new chemotypes with reasonable calibration.<\/li>\n<\/ul>\n\n\n\n<p>In one cardiometabolic program, a multi-task network flagged unexpected similarity between a lead compound and a known hERG binder that our rule\u2011based system missed. Follow\u2011up patch\u2011clamp studies confirmed a concerning signal, and the program pivoted early, exactly the kind of failure you <em>want<\/em> to have in silico.<\/p>\n\n\n\n<p>But, toxicity prediction is far from solved. Reviews (e.g., <strong><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12472608\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">recent systematic review on AI toxicity prediction methods<\/a><\/strong>, <strong><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11292590\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">analysis of machine learning in toxicology<\/a><\/strong>) repeatedly show good cross\u2011validation but modest performance in external, prospective tests. That&#8217;s why I push teams to treat these models as risk\u2011screening tools, not green lights.<\/p>\n\n\n\n<figure class=\"wp-block-gallery has-nested-images columns-default is-cropped wp-block-gallery-3 is-layout-flex wp-block-gallery-is-layout-flex\">\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" src=\"https:\/\/dr7.ai\/blog\/wp-content\/uploads\/2025\/11\/image-20.png\" alt=\"\" \/><\/figure>\n<\/figure>\n\n\n<h3 class=\"wp-block-heading\" id=\"enhancing-clinical-trial-analysis-with-aidriven-insights\"><span class=\"ez-toc-section\" id=\"Enhancing_Clinical_Trial_Analysis_with_AI-Driven_Insights\"><\/span>Enhancing Clinical Trial Analysis with AI-Driven Insights<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n<p>On the clinical side, I see three credible uses today:<\/p>\n\n\n\n<ol start=\"1\" class=\"wp-block-list\">\n<li><strong>Eligibility and recruitment: <a href=\"https:\/\/www.nih.gov\/news-events\/news-releases\/nih-developed-ai-algorithm-matches-potential-volunteers-clinical-trials\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">NIH&#8217;s AI algorithm for matching volunteers to clinical trials<\/a><\/strong>has shown promising results. In a large academic center I worked with, a similar NLP pipeline screened EHR notes and labs, increasing candidate identification by ~25% for a rare disease trial, under strict HIPAA\/GDPR controls.<\/li>\n\n\n\n<li><strong>Adaptive enrichment:<\/strong> ML models can flag subgroups with differential response early, feeding into adaptive designs (with pre\u2011specified rules and DMC oversight).<\/li>\n\n\n\n<li><strong>Signal detection:<\/strong> time\u2011to\u2011event modeling, adverse event clustering, and longitudinal biomarker analysis benefit from modern ML, especially when missingness and censoring are substantial.<\/li>\n<\/ol>\n\n\n\n<p>Critical guardrails:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Every model used operationally in a trial must have a <strong>locked specification<\/strong>, audit trail, and change-control process.<\/li>\n\n\n\n<li>Patient\u2011facing decisions still rest with investigators: AI suggestions should be explainable enough to withstand IRB and regulator scrutiny.<\/li>\n<\/ul>\n\n\n<h2 class=\"wp-block-heading\" id=\"success-stories-aidriven-breakthroughs-in-drug-discovery\"><span class=\"ez-toc-section\" id=\"Success_Stories_AI-Driven_Breakthroughs_in_Drug_Discovery\"><\/span>Success Stories: AI-Driven Breakthroughs in Drug Discovery<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<h3 class=\"wp-block-heading\" id=\"promising-drug-candidates-discovered-through-ai-technology\"><span class=\"ez-toc-section\" id=\"Promising_Drug_Candidates_Discovered_through_AI_Technology\"><\/span>Promising Drug Candidates Discovered through AI Technology<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n<p>The public narrative is full of &#8220;first AI\u2011discovered drug&#8221; headlines. When I dig into the details (e.g., case studies summarized in Front Pharmacol 2025 and Drug Target Review 2023), the pattern is more grounded:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>AI typically <strong>accelerates hit or lead identification<\/strong> by 6\u201312 months.<\/li>\n\n\n\n<li>The compounds still go through traditional medicinal chemistry, preclinical, and clinical gauntlets.<\/li>\n<\/ul>\n\n\n\n<p>In a real-world oncology collaboration I supported, AI rescoring of fragment screens uncovered a weak binder that conventional analysis had down\u2011ranked. That fragment eventually seeded a lead series that&#8217;s now in Phase I. Was AI the sole hero? No. But without it, that fragment would probably still be sitting in a CSV file.<\/p>\n\n\n<h3 class=\"wp-block-heading\" id=\"leading-ai-tools-revolutionizing-pharmaceutical-rampd-eg-alphafold\"><span class=\"ez-toc-section\" id=\"Leading_AI_Tools_Revolutionizing_Pharmaceutical_R_D_eg_AlphaFold\"><\/span>Leading AI Tools Revolutionizing Pharmaceutical R&amp;D (e.g., AlphaFold)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n<p>A few tools genuinely changed the baseline:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>AlphaFold \/ AlphaFold3+<\/strong>: high-accuracy structure prediction (DeepMind, <strong><a href=\"https:\/\/www.technologyreview.com\/2025\/11\/24\/1128322\/whats-next-for-alphafold-a-conversation-with-a-google-deepmind-nobel-laureate\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">MIT Tech Review conversation with AlphaFold Nobel laureate<\/a><\/strong>) lets teams model previously intractable proteins and protein\u2013protein complexes. I&#8217;ve seen it unlock structure\u2011based campaigns for membrane proteins we previously ignored.<\/li>\n\n\n\n<li><strong>Generative chemistry platforms<\/strong> (e.g., BioNeMo, proprietary pharma stacks): enable fast multi\u2011objective optimization, tightly integrated with docking and ADMET models.<\/li>\n\n\n\n<li><strong>AI\u2011driven knowledge graphs<\/strong>: used at several large pharmas to connect literature, omics, and internal data for target and indication expansion.<\/li>\n<\/ul>\n\n\n\n<p>Still, I remind teams that these tools are <em>components<\/em> of a GxP ecosystem. Without robust data engineering, lineage tracking, and human review, even the best model is just an impressive side project.<\/p>\n\n\n<h2 class=\"wp-block-heading\" id=\"the-future-of-ai-in-drug-discovery-benefits-and-ongoing-challenges\"><span class=\"ez-toc-section\" id=\"The_Future_of_AI_in_Drug_Discovery_Benefits_and_Ongoing_Challenges\"><\/span>The Future of AI in Drug Discovery: Benefits and Ongoing Challenges<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<h3 class=\"wp-block-heading\" id=\"accelerating-drug-development-and-personalizing-treatments-with-ai\"><span class=\"ez-toc-section\" id=\"Accelerating_Drug_Development_and_Personalizing_Treatments_with_AI\"><\/span>Accelerating Drug Development and Personalizing Treatments with AI<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n<p>Looking ahead, I expect the most meaningful impact of AI in drug discovery to come from:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Tighter loops between real\u2011world data and discovery.<\/strong> Post\u2011marketing safety and effectiveness data feeding back into target selection and next\u2011gen molecule design.<\/li>\n\n\n\n<li><strong>Patient\u2011stratified therapeutics.<\/strong> ML\u2011defined endotypes guiding which drug, at what dose, for which molecularly defined subgroup, especially in oncology, immunology, and rare diseases.<\/li>\n\n\n\n<li><strong>Automation of routine modeling.<\/strong> Well\u2011validated, regulated AI services for ADMET, DDI prediction, and exposure\u2013response modeling that can be reused across sponsors.<\/li>\n<\/ul>\n\n\n\n<p>But personalization brings new risks: data privacy (HIPAA\/GDPR), algorithmic bias across ancestry and socioeconomic groups, and the temptation to overfit to small responder subsets.<\/p>\n\n\n<h3 class=\"wp-block-heading\" id=\"overcoming-validation-and-regulatory-challenges-in-aidriven-drug-discovery\"><span class=\"ez-toc-section\" id=\"Overcoming_Validation_and_Regulatory_Challenges_in_AI-Driven_Drug_Discovery\"><\/span>Overcoming Validation and Regulatory Challenges in AI-Driven Drug Discovery<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n<p>Here&#8217;s where many promising AI efforts stall. Regulators are becoming clearer: the FDA&#8217;s CDER has published discussion papers and a proposed framework for AI in drug development and submissions (<strong><a href=\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-proposes-framework-advance-credibility-ai-models-used-drug-and-biological-product-submissions\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">FDA&#8217;s proposed framework for AI model credibility<\/a><\/strong>, <strong><a href=\"https:\/\/www.fda.gov\/about-fda\/center-drug-evaluation-and-research-cder\/artificial-intelligence-drug-development\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">FDA Center for Drug Evaluation on AI in drug development<\/a><\/strong>). The themes align well with what I recommend internally:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Model credibility &amp; transparency:<\/strong> document training data, validation strategy, performance, and limitations in a way that can go into an eCTD.<\/li>\n\n\n\n<li><strong>Lifecycle management:<\/strong> treat AI as a &#8220;learning system&#8221; with pre\u2011specified update policies, monitoring, and change controls.<\/li>\n\n\n\n<li><strong>Context\u2011of\u2011use clarity:<\/strong> be specific, are you using the model for internal decision support, as part of exposure\u2013response modeling in a submission, or to drive adaptive randomization? Each has different evidence requirements.<\/li>\n<\/ul>\n\n\n\n<p>In my practice, the most successful teams:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Run <strong>prospective, pre\u2011registered validation<\/strong> of key AI models, ideally in collaboration with academic or consortia partners.<\/li>\n\n\n\n<li>Maintain <strong>model risk registers<\/strong> analogous to safety risk registers.<\/li>\n\n\n\n<li>Involve regulatory affairs from day one rather than at the moment of submission.<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\" \/>\n\n\n\n<p><strong>Medical &amp; Regulatory Disclaimer (Read This Part)<\/strong><\/p>\n\n\n\n<p>I&#8217;m sharing technical and clinical perspectives for informational and educational purposes only. This article is <strong>not<\/strong> medical advice, treatment guidance, or regulatory counsel, and it shouldn&#8217;t be used to diagnose or treat any condition, or to design, run, or modify clinical trials without proper oversight. Drug development decisions must be made by qualified professionals, following local regulations, institutional policies, and up\u2011to\u2011date guidelines.<\/p>\n\n\n\n<p>Always consult your organization&#8217;s medical, regulatory, and legal experts before applying any of these concepts. Do <strong>not<\/strong> change patient care, dosing, or trial procedures based on this article. If you&#8217;re a patient or caregiver, speak with your clinician before making any health decisions. In any situation involving acute or severe symptoms, seek emergency care immediately.<\/p>\n\n\n\n<p><strong>Conflict of Interest Statement<\/strong><\/p>\n\n\n\n<p>I do not hold equity in, nor am I compensated by, any of the specific tools or platforms mentioned in this text at the time of writing (updated November 2025).<\/p>\n\n\n<h2 class=\"wp-block-heading\" id=\"frequently-asked-questions-about-ai-in-drug-discovery\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_about_AI_in_Drug_Discovery\"><\/span>Frequently Asked Questions about AI in Drug Discovery<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<h3 class=\"wp-block-heading\" id=\"what-is-ai-in-drug-discovery-and-where-does-it-add-the-most-value-today\"><span class=\"ez-toc-section\" id=\"What_is_AI_in_drug_discovery_and_where_does_it_add_the_most_value_today\"><\/span>What is AI in drug discovery and where does it add the most value today?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n<p>AI in drug discovery uses machine learning and generative models to prioritize targets, design and rank molecules, predict ADMET and toxicity, and analyze clinical trial data. The biggest value today is focusing resources\u2014avoiding dead-end chemotypes and low\u2011probability programs rather than instantly delivering \u201cAI-discovered\u201d drugs.<\/p>\n\n\n<h3 class=\"wp-block-heading\" id=\"how-does-ai-in-drug-discovery-reduce-time-and-cost-in-pharmaceutical-rampd\"><span class=\"ez-toc-section\" id=\"How_does_AI_in_drug_discovery_reduce_time_and_cost_in_pharmaceutical_R_D\"><\/span>How does AI in drug discovery reduce time and cost in pharmaceutical R&amp;D?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n<p>AI reduces time and cost by automating in silico triage, reusing validated ADMET and safety models across programs, and improving early prediction of toxicity and lack of efficacy. The savings appear when AI models are embedded in decision gates, not run as side experiments that don\u2019t affect portfolio choices.<\/p>\n\n\n<h3 class=\"wp-block-heading\" id=\"how-are-generative-ai-models-used-for-molecule-design-and-optimization\"><span class=\"ez-toc-section\" id=\"How_are_generative_AI_models_used_for_molecule_design_and_optimization\"><\/span>How are generative AI models used for molecule design and optimization?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n<p>Generative AI models propose novel or optimized molecules from SMILES or graph representations, conditioned on properties like potency, selectivity, and ADMET. They support de novo ideation and scaffold optimization, but must be paired with PAINS filters, retrosynthetic analysis, and medicinal chemistry review to avoid unstable, implausible, or trivially derivative structures.<\/p>\n\n\n<h3 class=\"wp-block-heading\" id=\"what-are-the-main-regulatory-challenges-for-using-ai-in-drug-discovery\"><span class=\"ez-toc-section\" id=\"What_are_the_main_regulatory_challenges_for_using_AI_in_drug_discovery\"><\/span>What are the main regulatory challenges for using AI in drug discovery?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n<p>Key regulatory challenges include demonstrating model credibility, documenting data lineage and validation, managing AI as a learning system with change control, and clearly defining context of use. FDA expectations increasingly emphasize transparency, prospective validation, and audit trails, especially when AI outputs influence submissions or clinical trial decisions.<\/p>\n\n\n<h3 class=\"wp-block-heading\" id=\"how-can-a-pharma-or-biotech-company-practically-start-implementing-ai-in-drug-discovery\"><span class=\"ez-toc-section\" id=\"How_can_a_pharma_or_biotech_company_practically_start_implementing_AI_in_drug_discovery\"><\/span>How can a pharma or biotech company practically start implementing AI in drug discovery?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n<p>Start with high\u2011quality, well\u2011curated internal data and a narrowly defined use case, such as ADMET triage or target reprioritization. Build auditable pipelines with versioned models and clear validation plans. Involve medicinal chemists, clinicians, statisticians, and regulatory affairs early so AI outputs map cleanly onto existing GxP workflows.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\" \/>\n\n\n\n<p><strong>Past Review:<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-embed is-type-wp-embed is-provider-dr-7-ai-content-center wp-block-embed-dr-7-ai-content-center\"><div class=\"wp-block-embed__wrapper\">\n<blockquote class=\"wp-embedded-content\" data-secret=\"C07qHXa0El\"><a href=\"https:\/\/dr7.ai\/blog\/model\/biogpt-and-beyond-ai-models-for-biomedical-literature-analysis\/\">BioGPT in Biomedical NLP: Benchmarks, Risks &amp; Workflows<\/a><\/blockquote><iframe class=\"wp-embedded-content\" sandbox=\"allow-scripts\" security=\"restricted\" style=\"position: absolute; visibility: hidden;\" title=\"&#8220;BioGPT in Biomedical NLP: Benchmarks, Risks &amp; Workflows&#8221; &#8212; Dr7.ai  Content Center\" src=\"https:\/\/dr7.ai\/blog\/model\/biogpt-and-beyond-ai-models-for-biomedical-literature-analysis\/embed\/#?secret=fvup5H4TSw#?secret=C07qHXa0El\" data-secret=\"C07qHXa0El\" width=\"500\" height=\"282\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\"><\/iframe>\n<\/div><\/figure>\n\n\n\n<figure class=\"wp-block-embed is-type-wp-embed is-provider-dr-7-ai-content-center wp-block-embed-dr-7-ai-content-center\"><div class=\"wp-block-embed__wrapper\">\n<blockquote class=\"wp-embedded-content\" data-secret=\"OcvPW7w0nC\"><a href=\"https:\/\/dr7.ai\/blog\/model\/pen-source-vs-proprietary-medical-ai-models-how-to-choose-for-your-project\/\">Open vs Proprietary Medical AI: Choosing the Right Approach<\/a><\/blockquote><iframe class=\"wp-embedded-content\" sandbox=\"allow-scripts\" security=\"restricted\" style=\"position: absolute; visibility: hidden;\" title=\"&#8220;Open vs Proprietary Medical AI: Choosing the Right Approach&#8221; &#8212; Dr7.ai  Content Center\" src=\"https:\/\/dr7.ai\/blog\/model\/pen-source-vs-proprietary-medical-ai-models-how-to-choose-for-your-project\/embed\/#?secret=aOYQGwLdNu#?secret=OcvPW7w0nC\" data-secret=\"OcvPW7w0nC\" width=\"500\" height=\"282\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\"><\/iframe>\n<\/div><\/figure>\n\n\n\n<figure class=\"wp-block-embed is-type-wp-embed is-provider-dr-7-ai-content-center wp-block-embed-dr-7-ai-content-center\"><div class=\"wp-block-embed__wrapper\">\n<blockquote class=\"wp-embedded-content\" data-secret=\"ObhMZbnI8U\"><a href=\"https:\/\/dr7.ai\/blog\/medical\/2025-medical-ai-api-integration-guide-hipaa-compliant\/\">2025 Medical AI API Integration Guide (HIPAA-Compliant)<\/a><\/blockquote><iframe class=\"wp-embedded-content\" sandbox=\"allow-scripts\" security=\"restricted\" style=\"position: absolute; visibility: hidden;\" title=\"&#8220;2025 Medical AI API Integration Guide (HIPAA-Compliant)&#8221; &#8212; Dr7.ai  Content Center\" src=\"https:\/\/dr7.ai\/blog\/medical\/2025-medical-ai-api-integration-guide-hipaa-compliant\/embed\/#?secret=icXpPkBCwh#?secret=ObhMZbnI8U\" data-secret=\"ObhMZbnI8U\" width=\"500\" height=\"282\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\"><\/iframe>\n<\/div><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Disclaimer: The content on this website is for informational and educational purposes only and is intended to help readers understand AI technologies used in healthcare settings. It does not provide medical advice, diagnosis, treatment, or clinical guidance. Any medical decisions must be made by qualified healthcare professionals. AI models, tools, or workflows described here are [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":2819,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":"","beyondwords_generate_audio":"","beyondwords_project_id":"","beyondwords_content_id":"","beyondwords_preview_token":"","beyondwords_player_content":"","beyondwords_player_style":"","beyondwords_language_code":"","beyondwords_language_id":"","beyondwords_title_voice_id":"","beyondwords_body_voice_id":"","beyondwords_summary_voice_id":"","beyondwords_error_message":"","beyondwords_disabled":"","beyondwords_delete_content":"","beyondwords_podcast_id":"","beyondwords_hash":"","publish_post_to_speechkit":"","speechkit_hash":"","speechkit_generate_audio":"","speechkit_project_id":"","speechkit_podcast_id":"","speechkit_error_message":"","speechkit_disabled":"","speechkit_access_key":"","speechkit_error":"","speechkit_info":"","speechkit_response":"","speechkit_retries":"","speechkit_status":"","speechkit_updated_at":"","_speechkit_link":"","_speechkit_text":""},"categories":[3],"tags":[],"class_list":["post-2815","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-model"],"uagb_featured_image_src":{"full":["https:\/\/dr7.ai\/blog\/wp-content\/uploads\/2025\/11\/1280X1280-2-6.png",1280,698,false],"thumbnail":["https:\/\/dr7.ai\/blog\/wp-content\/uploads\/2025\/11\/1280X1280-2-6-150x150.png",150,150,true],"medium":["https:\/\/dr7.ai\/blog\/wp-content\/uploads\/2025\/11\/1280X1280-2-6-300x164.png",300,164,true],"medium_large":["https:\/\/dr7.ai\/blog\/wp-content\/uploads\/2025\/11\/1280X1280-2-6-768x419.png",768,419,true],"large":["https:\/\/dr7.ai\/blog\/wp-content\/uploads\/2025\/11\/1280X1280-2-6-1024x558.png",1024,558,true],"1536x1536":["https:\/\/dr7.ai\/blog\/wp-content\/uploads\/2025\/11\/1280X1280-2-6.png",1280,698,false],"2048x2048":["https:\/\/dr7.ai\/blog\/wp-content\/uploads\/2025\/11\/1280X1280-2-6.png",1280,698,false]},"uagb_author_info":{"display_name":"Andychen","author_link":"https:\/\/dr7.ai\/blog\/author\/andychen\/"},"uagb_comment_info":0,"uagb_excerpt":"Disclaimer: The content on this website is for informational and educational purposes only and is intended to help readers understand AI technologies used in healthcare settings. It does not provide medical advice, diagnosis, treatment, or clinical guidance. Any medical decisions must be made by qualified healthcare professionals. AI models, tools, or workflows described here are&hellip;","_links":{"self":[{"href":"https:\/\/dr7.ai\/blog\/wp-json\/wp\/v2\/posts\/2815","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dr7.ai\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dr7.ai\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dr7.ai\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/dr7.ai\/blog\/wp-json\/wp\/v2\/comments?post=2815"}],"version-history":[{"count":1,"href":"https:\/\/dr7.ai\/blog\/wp-json\/wp\/v2\/posts\/2815\/revisions"}],"predecessor-version":[{"id":2824,"href":"https:\/\/dr7.ai\/blog\/wp-json\/wp\/v2\/posts\/2815\/revisions\/2824"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dr7.ai\/blog\/wp-json\/wp\/v2\/media\/2819"}],"wp:attachment":[{"href":"https:\/\/dr7.ai\/blog\/wp-json\/wp\/v2\/media?parent=2815"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dr7.ai\/blog\/wp-json\/wp\/v2\/categories?post=2815"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dr7.ai\/blog\/wp-json\/wp\/v2\/tags?post=2815"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}